Replies to post #250551 on Biotech Values

[DewDiligence]

GILD acquires CBAY for $32.50 cash—a 27% premium to Friday’s close:

https://finance.yahoo.com/news/gilead-sciences-expands-liver-portfolio-133000610.html

CBAY has no approved drugs, but CBAY’s Seladelpar is under FDA review for PBC with a PDUFA date of 8/14/24. Seladelpar previously failed in NASH.

The nominal deal value is $4.3B.